The following FTSE listed stocks First Property (LON: FPO), Latham (LON: LTHM), Persimmon (LON: PSN), Puretech Health (LON: PRTC), GlaxoSmithKline (LON: GSK) are set to make headlines today.
- First Property Group plc (LON: FPO)
FTSE AIM All-Share index constituent First Property Group, a property fund manager and investor, announced its preliminary FY 2021 results today, for the period ending twelve months to 31 March 2021.
FPO reported a loss before tax of £5.09 million in FY 2021 compared to a profit before tax of £5.52 million in FY 2020. However, its cash reserves increased to £16.24 million from £7.34 million in the year before.
FPO’s shares closed at GBX 35.15, down by 0.28 per cent on 23 June.
- Latham (James) Plc (LON: LTHM)
Latham (James) Plc, one of the UK’s largest independent trade distributors of timber, decorative surfaces and panels and an FTSE AIM All-Share index constituent, reported a revenue increase of 1.3 per cent to £250.2 million for FY 2021 this morning, as compared to £247.1 million in FY 2020. It’s like-for-like volumes also increased by 6.6 per cent in FY 2021, with a majority of the growth coming from its delivered business.
The company’s profit before tax increased by £2.9 million to £18.6m in FY 2021, from £15.7 million in the year before.
LTHM’s shares had closed at GBX 1,080.00, up by 4.85 per cent on 23 June.
- Persimmon Plc (LON: PSN)
FTSE 100 listed homebuilding company Persimmon has agreed to adhere to several voluntary undertakings following an investigation from the UK competition regulatory body, the Competition and Markets Authority (CMA) related to overcharging and high ground rent terms.
PSN agreed to extend its Right to buy scheme and cap its freehold buying price at £2,000, repayment to freehold homeowners who paid more than the price of £2,000 and an extension of its home buyer reservation period from 35 to 42 days.
PSN’s shares closed at GBX 2,975.00, down by 1.72 per cent on 23 June.
- Puretech Health Plc (LON: PRTC)
FTSE 250 index constituent Puretech Health, a clinical stage bio-therapeutics company, announced late Wednesday that tis founded entity Karuna reported results from its completed Phase 1b trial.
The trial was aimed at evaluating the safety and tolerability of KarXT (xanomeline-trospium) in healthy elderly volunteers. The results were consistent with prior trials.
PRTC has an 8.2 per cent ownership of Karuna and a right to royalty payments as a percentage of Karuna’s net sales.
PRTC’s shares closed at GBX 346.00, down by 0.29 per cent on 23 June.
- GlaxoSmithKline Plc (LON: GSK)
FTSE 100 index listed company GlaxoSmithKline, a UK-based multinational pharmaceutical major, announced a new strategy and growth outlook on Wednesday, as GSK confirmed plans to demerge its consumer healthcare business in mid 2022.
The new GSK targets a sale growth of more than 5 per cent and adjusted operating growth over 10 per cent between 2021 and 2026 on a CAGR basis. Additionally, the new GSK company targets sales of up to £33 billion by 2031.
It also announced its 2022 aggregate divided for GSK and the new consumer healthcare business to be at about 55 pence per share.
GSK’s shares closed at GBX 1,409.20, up by 1.03 per cent on 23 June.